PT3483163T - Novos derivados de triazolo[4,5-d]pirimidina como antagonistas de receptor cb2 - Google Patents

Novos derivados de triazolo[4,5-d]pirimidina como antagonistas de receptor cb2

Info

Publication number
PT3483163T
PT3483163T PT182069435T PT18206943T PT3483163T PT 3483163 T PT3483163 T PT 3483163T PT 182069435 T PT182069435 T PT 182069435T PT 18206943 T PT18206943 T PT 18206943T PT 3483163 T PT3483163 T PT 3483163T
Authority
PT
Portugal
Prior art keywords
triazolo
receptor antagonists
pyrimidine derivatives
pyrimidine
derivatives
Prior art date
Application number
PT182069435T
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PT3483163T publication Critical patent/PT3483163T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
PT182069435T 2013-09-06 2014-09-03 Novos derivados de triazolo[4,5-d]pirimidina como antagonistas de receptor cb2 PT3483163T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13183385 2013-09-06

Publications (1)

Publication Number Publication Date
PT3483163T true PT3483163T (pt) 2021-08-24

Family

ID=49111076

Family Applications (2)

Application Number Title Priority Date Filing Date
PT182069435T PT3483163T (pt) 2013-09-06 2014-09-03 Novos derivados de triazolo[4,5-d]pirimidina como antagonistas de receptor cb2
PT14761320T PT3041843T (pt) 2013-09-06 2014-09-03 Derivados de triazolo[4,5-d]pirimidina como agonistas do recetor cb2

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT14761320T PT3041843T (pt) 2013-09-06 2014-09-03 Derivados de triazolo[4,5-d]pirimidina como agonistas do recetor cb2

Country Status (32)

Country Link
US (1) US9593123B2 (pt)
EP (3) EP3943497A1 (pt)
JP (1) JP6441356B2 (pt)
KR (3) KR20220140651A (pt)
CN (1) CN105555788B (pt)
AR (1) AR097553A1 (pt)
AU (1) AU2014317229B2 (pt)
CA (1) CA2915766C (pt)
CL (1) CL2016000495A1 (pt)
CR (1) CR20160076A (pt)
DK (2) DK3041843T3 (pt)
EA (1) EA028335B1 (pt)
ES (2) ES2714094T3 (pt)
HK (1) HK1219277A1 (pt)
HR (2) HRP20190361T1 (pt)
HU (2) HUE041760T2 (pt)
IL (1) IL243092B (pt)
LT (2) LT3041843T (pt)
MA (1) MA38826B1 (pt)
MX (2) MX367084B (pt)
MY (1) MY191628A (pt)
PE (2) PE20160691A1 (pt)
PH (1) PH12016500250A1 (pt)
PL (2) PL3041843T3 (pt)
PT (2) PT3483163T (pt)
RS (2) RS58390B1 (pt)
SG (1) SG11201601714UA (pt)
SI (2) SI3041843T1 (pt)
TR (1) TR201900662T4 (pt)
TW (1) TWI705966B (pt)
UA (1) UA116395C2 (pt)
WO (1) WO2015032769A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015162630A1 (en) * 2014-04-25 2015-10-29 Anlon Chemical Research Organization Novel processes for preparing triazolo [4,5-d]- pyrimidines, including ticagrelor, vianew intermediates and new route of synthesis.
EP3215506B1 (en) 2014-11-07 2019-01-02 F.Hoffmann-La Roche Ag Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2
WO2017004133A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
CN107001405B (zh) * 2015-11-06 2019-03-05 江苏恒瑞医药股份有限公司 制备坎格雷洛中间体的方法
EP4108665A1 (en) 2016-06-23 2022-12-28 F. Hoffmann-La Roche AG [1,2,3]triazolo[4,5-d]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor
EP3475281A1 (en) 2016-06-23 2019-05-01 H. Hoffnabb-La Roche Ag Novel [1,2,31triazolo[4,5-d]pyrimidine derivatives
CN109311895B (zh) 2016-06-23 2021-06-18 豪夫迈·罗氏有限公司 新型[1,2,3]三唑并[4,5-d]嘧啶衍生物
JP7090037B2 (ja) * 2016-06-23 2022-06-23 エフ．ホフマン－ラ ロシュ アーゲー 新規な［１，２，３］トリアゾロ［４，５－ｄ］ピリミジン誘導体
CN106478639B (zh) * 2016-09-05 2018-09-18 郑州大学 嘧啶并1,2,4–三氮唑类的lsd1抑制剂、其制备方法及应用
CN106432248B (zh) * 2016-09-27 2018-11-27 郑州大学 含嘧啶并三氮唑类lsd1抑制剂、其制备方法及应用
CN106432247B (zh) * 2016-09-27 2018-06-29 郑州大学 含有腙键的嘧啶并三氮唑类化合物、制备方法及其应用
CN106928296A (zh) * 2017-02-06 2017-07-07 上海华升生物科技有限公司 一种2‑(3,3,3‑三氟丙硫基)腺苷的合成方法
CN106928235A (zh) * 2017-05-03 2017-07-07 郑州大学 含嘧啶并三氮唑类lsd1抑制剂、其制备方法及应用
CN107033148B (zh) * 2017-05-03 2018-10-26 郑州大学 含嘧啶并三氮唑—巯基四氮唑类lsd1抑制剂、其制备方法及应用
CN109516990B (zh) * 2017-09-19 2021-06-01 天津药物研究院有限公司 嘧啶并三氮唑类化合物、其制备方法和用途
CN113582935A (zh) * 2021-08-27 2021-11-02 中国医学科学院放射医学研究所 一种炎症小体核苷酸结合寡聚化结构域样受体蛋白3抑制剂及其制备方法和应用
CN115246832A (zh) * 2022-06-15 2022-10-28 深圳湾实验室 一类去泛素化酶usp25和usp28靶向抑制剂及制备和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL134748A0 (en) 1997-09-02 2001-04-30 Du Pont Pharm Co Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
WO2001058869A2 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
CN101060841A (zh) * 2004-06-17 2007-10-24 加利福尼亚大学董事会 拮抗腺苷a2a受体来改善成瘾行为的一种或多种构成
AR051596A1 (es) 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
EP2155747B1 (en) 2007-05-10 2012-10-24 GE Healthcare Limited Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US9271962B2 (en) 2008-03-17 2016-03-01 Northeastern University Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors
WO2010120987A1 (en) 2009-04-17 2010-10-21 Wyeth Llc Ring fused, ureidoaryl- and carbamoylaryl-bridged morpholino-pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
WO2013060837A1 (en) 2011-10-27 2013-05-02 Lek Pharmaceuticals D.D. Synthesis of triazolopyrimidine compounds
UA111640C2 (uk) * 2011-11-08 2016-05-25 Ф. Хоффманн-Ля Рош Аг ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
US9067943B2 (en) * 2011-11-25 2015-06-30 Hoffmann-La Roche Inc. [1,2,3]triazolo[4,5-D]pyrimidine derivatives
WO2014005968A1 (en) 2012-07-04 2014-01-09 F. Hoffmann-La Roche Ag Novel adamantyl derivatives as cannabinoid receptor 2 agonists
PE20151073A1 (es) 2012-12-07 2015-07-25 Hoffmann La Roche Piridina-2-amidas utiles como agonistas de cb2
US9512141B2 (en) 2012-12-07 2016-12-06 Hoffmann-La Roche Inc. Pyrazine derivatives as CB2 receptor agonists
US9303012B2 (en) 2012-12-07 2016-04-05 Hoffman-La Roche Inc. Pyridine-2-amides useful as CB2 agonists
EP3357918A1 (en) 2012-12-07 2018-08-08 F. Hoffmann-La Roche AG Novel pyridine derivatives
SG11201507168XA (en) 2013-03-07 2015-10-29 Hoffmann La Roche Novel pyrazol derivatives
CA2907691A1 (en) 2013-05-02 2014-11-06 F. Hoffmann-La Roche Ag Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists
PL2991987T3 (pl) 2013-05-02 2018-10-31 F. Hoffmann-La Roche Ag Pochodne purynowe jako agoniści receptora CB2
RU2664644C2 (ru) 2013-06-11 2018-08-21 Ф. Хоффманн-Ля Рош Аг Новые производные тетразолона

Also Published As

Publication number Publication date
US20160168158A1 (en) 2016-06-16
HUE055201T2 (hu) 2021-11-29
AR097553A1 (es) 2016-03-23
CA2915766C (en) 2023-09-26
SI3483163T1 (sl) 2021-11-30
NZ756513A (en) 2021-05-28
CN105555788B (zh) 2018-11-23
US9593123B2 (en) 2017-03-14
EP3483163A3 (en) 2019-07-24
PT3041843T (pt) 2019-02-26
KR20210074404A (ko) 2021-06-21
WO2015032769A1 (en) 2015-03-12
DK3041843T3 (en) 2019-03-25
CL2016000495A1 (es) 2016-10-07
CN105555788A (zh) 2016-05-04
CA2915766A1 (en) 2015-03-12
LT3041843T (lt) 2019-03-12
NZ715085A (en) 2021-05-28
PE20191528A1 (es) 2019-10-23
UA116395C2 (uk) 2018-03-12
EA028335B1 (ru) 2017-11-30
PL3483163T3 (pl) 2021-11-22
MX2019009100A (es) 2019-09-16
MA38826A1 (fr) 2016-05-31
CR20160076A (es) 2016-04-01
PH12016500250B1 (en) 2016-05-16
IL243092B (en) 2019-06-30
TW201542551A (zh) 2015-11-16
PL3041843T3 (pl) 2019-06-28
HRP20190361T1 (hr) 2019-04-05
TWI705966B (zh) 2020-10-01
EP3041843B1 (en) 2019-01-02
EP3041843A1 (en) 2016-07-13
SI3041843T1 (sl) 2019-04-30
MY191628A (en) 2022-07-04
ES2714094T3 (es) 2019-05-27
TR201900662T4 (tr) 2019-02-21
KR102454344B1 (ko) 2022-10-14
MA38826B1 (fr) 2016-12-30
JP6441356B2 (ja) 2018-12-19
DK3483163T3 (da) 2021-08-30
AU2014317229B2 (en) 2018-11-08
HK1219277A1 (zh) 2017-03-31
EP3483163A2 (en) 2019-05-15
LT3483163T (lt) 2021-09-10
HUE041760T2 (hu) 2019-05-28
RS62234B1 (sr) 2021-09-30
KR102349567B1 (ko) 2022-01-11
EA201690478A1 (ru) 2016-06-30
RS58390B1 (sr) 2019-04-30
ES2883923T3 (es) 2021-12-09
KR20160050061A (ko) 2016-05-10
EP3483163B1 (en) 2021-06-23
PH12016500250A1 (en) 2016-05-16
IL243092A0 (en) 2016-02-01
PE20160691A1 (es) 2016-07-28
AU2014317229A1 (en) 2016-01-07
EP3943497A1 (en) 2022-01-26
JP2016532707A (ja) 2016-10-20
SG11201601714UA (en) 2016-04-28
MX367084B (es) 2019-08-05
HRP20211322T1 (hr) 2021-11-26
MX2016002117A (es) 2016-07-05
KR20220140651A (ko) 2022-10-18

Similar Documents

Publication Publication Date Title
HRP20190361T1 (hr) Derivati triazolo[4,5-d]pirimidina kao antagonisti cb2 receptora
HK1245764A1 (zh) 3-取代的5-氨基-6h-噻唑並[4，5-d]嘧啶-2，7-二酮化合物
ZA201506570B (en) 2-phenylimidazo[1,2-a]pyrimidines as imaging agents
ZA201402905B (en) [1,2,3]triazolo [4,5-d]pyrimidine derivatives as agonist of the cannabinoid receptor 2
IL242162B (en) Pyrrolo [2, 3 –d] pyrimidine derivatives as 2cb receptor agonists
IL232304A0 (en) [1,2,3]-Triazolo[4,5-d]pyrimidine derivatives are agonistic for cannabinoid receptor 2 agonists
ZA201406323B (en) Triazolo[4,5-d]pyrimidine derivatives
IL250983A0 (en) Triazolo[4, 5-d]pyrimidines as cannabinoid receptor 2 agonists
ZA201605666B (en) Pyrazolo[1,5-a]pyrimidines as antiviral compounds
TH1601001194A (th) อนุพันธ์ไตรอะโซโล[4,5-d]ไพริมิดีน ใหม่